Piper Jaffray Raises Price Target on Insulet (PODD) to $41 Following 2Q Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Insulet Reports Second Quarter 2015 Financial Results
August 12, 2015 4:01 PM EDTBILLERICA, Mass., Aug. 12, 2015 /PRNewswire/ -- Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the three months ended June 30, 2015.       Â
Second Quarter Highlights and Recent Developments:
Second quarter financial results: Total revenue of $75.6 million exceeds Company's prior expectations of $67 to $70 million. U.S. OmniPod revenue of $44.7 million. International OmniPod revenue of $7.7 million. Drug Delivery revenue of $7.5 million. Neighborhood Diabetes revenue of $15.7 million. Announced today appointment of Michael... More